Edwin has a B.Sc and Ph.D. from Sheffield University. He received a Royal Society/NATO fellowship to carry out post-doctoral research at the University of Regensburg, Germany. Edwin began a successful commercial career at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a £120M flotation on the LSE in 1998. This was followed by a sale of the company to Evotec Biosystems in 2000 for £316M.
From 2000, Edwin has played an important role at Board level (primarily as Chairman) in over 15 European life science companies. During this time, he was involved in a number of financing rounds, a series of M&A transactions and multiple IPOs. In 2004, he was appointed Chairman of Ablynx and in 2006 he was appointed CEO.
Since becoming CEO of Ablynx, the company successfully completed an €85M IPO on Euronext in 2007 and in 2017 a $230M IPO on Nasdaq. Over an 11 year period, Edwin has led the raising of >€700M in equity and debt financing and generated >€450M from collaborations, while the company has grown from 50 to almost 500 people and is poised to commercialize its first pharmaceutical product.
MEET EDWIN MOSES AT #KFG2018
Edwin Moses will present a plenary talk in the morning programme.